KT-474 is under clinical development by Kymera Therapeutics and currently in Phase I for Hidradenitis Suppurativa. According to GlobalData, Phase I drugs for Hidradenitis Suppurativa have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KT-474’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KT-474 (KYM-001) is under development for the treatment of B-cell like (ABC) diffuse large B cell lymphoma (DLBCL) and inflammation disorders like hidradenitis suppurativa, rheumatoid arthritis, atopic dermatitis (AD). The drug candidate is administered by oral route in the form of tablet. The drug candidate is a heterobifunctional PROTAC (proteolysis-targeting chimera) being developed based on protein degradation platform. The drug candidate acts by targeting IRAK4.
Kymera Therapeutics overview
Kymera Therapeutics (Kymera) is a clinical stage biopharma and technology company involved in developing small molecule therapeutics for protein degradation. The companiy’s pipeline product portfolio comprise IRAK4, IRAKIMiD, STAT3 and MDM2. Its targeted protein degradation platform Pegasus, an information technology powered platform that allows the discovery of selective small molecule protein degraders against disease-causing proteins throughout the body. The company also carries out research and discovery of breakthrough drugs addressing novel medical areas. Its product find application in cancers, inflammatory, autoimmune and other related diseases. Kymera is headquartered in Watertown, Massachusetts, the US.
For a complete picture of KT-474’s drug-specific PTSR and LoA scores, buy the report here.